Phase II study of amonafide in gastric adenocarcinoma : an Illinois cancer center trial

Twelve patients with recurrent, metastatic, or inoperable gastric adenocarcinoma were enrolled in an Illinois Cancer Center phase II trial of amonafide (nafidimide), a novel compound that acts as a DNA intercalator. Treatment consisted of a 60-minute infusion of amonafide which was administered dail...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Investigational new drugs 1994-01, Vol.12 (3), p.267-270
Hauptverfasser:	MULLANE, M. R, SCHILSKY, R. L, CARROLL, R. B, WADE, J. L, KILTON, L. J, BLOUGH, R. R, BAUMAN, A, FRENCH, S. L, BENSON, A. B
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - drug therapy Antineoplastic agents Antineoplastic Agents - therapeutic use Biological and medical sciences Female General aspects Hematologic Diseases - chemically induced Humans Imides - adverse effects Imides - therapeutic use Isoquinolines - adverse effects Isoquinolines - therapeutic use Male Medical sciences Naphthalimides Pharmacology. Drug treatments Stomach Neoplasms - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!